Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Pinnacle Clinical Research · University of Oxford · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
757
total citations
- FWCI
- 43.12
- Percentile
- 100%
- References
- 31
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Placebo
- Steatohepatitis
- Medicine
- Internal medicine
- Double blind
- Phase (matter)
- Physical therapy
- Fatty liver
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.